|
Mutation Information
|
Mutation Site
|
L180M |
|
Mutation Type
|
Amino acid level |
|
Gene/Protein/Region Type
|
RT |
|
Genotype/Subtype
|
C |
|
Relevant Drug
|
telbivudine (LDT);entecavir (ETV) |
|
Country
|
Korea |
Literature Information
|
PubMed PMID
|
28103819
|
|
Disease
|
HBV infection
|
|
Published Year
|
2017 |
|
Journal
|
BMC gastroenterology |
|
Title
|
Telbivudine versus entecavir in patients with undetectable hepatitis B virus DNA: a randomized trial. |
|
Author
|
An J,Lim YS,Kim GA,Han SB,Jeong W,Lee D,Shim JH,Lee HC,Lee YS |
|
Evidence
|
Eleven patients (23.4%) in the telbivudine group, but none in the entecavir group, experienced virologic breakthrough (P < 0.001). Seven patients (14.9%) exhibited genotypic resistance mutations (M204I +/- L180M) during the virologic breakthrough.
|
|
|
HBV Mutation Detail Information